Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program.Julien Taı̈eb, Alberto F. Sobrero, Salvatore Siena et al.|Journal of Clinical Oncology|2014Cited by 1